PRODUCT INFORMATION



NH₂

SLC5111312 (hydrochloride)

Item No. 23288

CAS Registry No.: 1870811-01-0

Formal Name: (2S,3S)-3-hydroxy-2-[3-[6-(pentyloxy)-

2-naphthalenyl]-1,2,4-oxadiazol-5-yl]-1-


pyrrolidinecarboximidamide, monohydrochloride

MF: C22H27N5O3 • HCI

445.9 FW: **Purity:** ≥98% UV/Vis.: λ_{max} : 237 nm Supplied as: A crystalline solid

Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

SLC5111312 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the SLC5111312 (hydrochloride) in the solvent of choice. SLC5111312 (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of SLC5111312 (hydrochloride) in these solvents is approximately 14, 3, and 2 mg/ml, respectively. SLC5111312 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SLC5111312 (hydrochloride) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. SLC5111312 (hydrochloride) has a solubility of approximately 0.2 mg/ml in a 1:4 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SLC5111312 is a dual inhibitor of sphingosine kinase 1 (SPHK1) and SPHK2 (K_i s = 0.73 and 0.9 μ M, respectively, using human recombinant kinases). SLC5111312 binding is selective for Sphk2 over Sphk1 in mice (K_i s = 1 and 20 μ M, respectively) but not rat (K_i s = 1.1 and 0.8 μ M, respectively).² It decreases cell-associated sphingosine-1-phosphate (S1P) and increases sphingosine in U937 monocytic leukemia cells at concentrations of 0.1 and 0.3 μ M. SLC5111312 (10 mg/kg) also decreases S1P in vivo in Sphk1^{-/-} but not in Sphk2^{-/-} mice and in rat, showing a functional selectivity for Sphk2 in mice.

References

- 1. Congdon, M.D., Kharel, Y., Brown, A.M., et al. Structure-activity relationship studies and molecular modeling of naphthalene-based sphingosine kinase 2 inhibitors. ACS Med. Chem. Lett. 7(3), 229-234 (2016).
- 2. Kharel, Y., Morris, E.A., Congdon, M.D., et al. Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels. J. Pharmacol. Exp. Ther. 355(1), 23-31 (2015).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/17/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM